Expanding horizons in the treatment of endometrial cancer: How can data from ESGO 2023 guide clinical practice?
Watch this activity exploring recent developments in the management of patients with endometrial cancer. This activity was filmed following the European Society of Gynaecological Oncology (ESGO) 2023 Congress, Istanbul, Turkey, 28 September–1 October 2023.
- Recognize the rationale and importance of molecular characterization in the management of EC
- Describe the efficacy data for new and emerging agents in treating advanced or recurrent EC
- Evaluate safety and practical considerations associated with new and emerging agents in treating advanced or recurrent EC and their impact on clinical practice
Case-based implementation of immune checkpoint inhibitors in endometrial cancer through shared decision making
Select a discussion in the hub to watch our multidisciplinary team share expert perspectives on the appropriate implementation of immune checkpoint inhibitors through shared decision making to ensure optimal outcomes for patients with endometrial cancer.
- Describe the current role and rationale for immunotherapy in the treatment of advanced or recurrent endometrial cancer
- Recognize the importance of a multidisciplinary approach for prognostic assessment and tailored treatment decisions in patients with advanced or recurrent endometrial cancer
- Outline the safety profile and adverse event management of immune checkpoint inhibitors in patients with endometrial cancer
Foreword – touchREVIEWS in Oncology & Haematology, Volume 19, Issue 2, 2023
In the latest edition of touchREVIEWS in Oncology & Haematology, we are pleased to present a collection of articles that delve into the latest research and advancements in the field. From innovative therapies and genetic treatments to analyses of digital patient education tools, each article contributes to our evolving understanding of complex medical conditions, offering […]
Cell-based Genetic Therapy for the Induction of Foetal Haemoglobin in Sickle Cell Disease and Transfusion-dependent β-thalassaemia
touchREVIEWS in Oncology & Haematology. 2023;19(2):29-32
Mutations of the β-globin gene (HBB) cause sickle cell disease and β-thalassaemia, collectively named the β-haemoglobinopathies. As mankind’s most common severe genetic diseases, where they are most prevalent, public health systems can be stressed.1–3 Asymptomatic heterozygous carriers are protected from severe P. falciparum infection. This has allowed the causative genes to reach polymorphic frequencies in some tropical […]
Findings from the XTEND-Kids Study: Efanesoctocog Alfa for Severe Haemophilia A in Children
touchREVIEWS in Oncology & Haematology. 2023;19(2):2-3
Severe haemophilia A (HA), defined as baseline factor VIII (FVIII) levels of <1%, results in traumatic and spontaneous bleeding episodes, which occur primarily in the joints, in addition to the muscles, soft tissue and the central nervous system. Prophylactic treatment is needed to prevent complications such as joint arthropathy.1 Treatment for HA has historically been achieved […]
Temozolomide for Paediatric High-Grade Glioma: Time for a Rethink?
touchREVIEWS in Oncology & Haematology. 2023;19(2):4-6
The management of children with diffuse midline gliomas (DMG) and other paediatric high-grade gliomas (pHGG) continue to present one of the most difficult challenges facing paediatric oncologists, characterized by poor patient outcomes.1 Standard of care therapy, which includes a maximal safe resection where possible, followed by focal radiation therapy, has remained unchanged for decades. This therapy, […]
Want To Know More About Our Journal?
Taking a balanced and practical view of the current clinical landscape in Oncology is at the heart of touchONCOLOGY and the journal we produce.
touchREVIEWS in Oncology and Haematology is a free-to-access, peer reviewed journal that aims to provide balanced and objective articles relevant to the day-to-day clinical setting.